
## Ada W Y Leung

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6232451/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Perspective – can copper complexes be developed as a novel class of therapeutics?. Dalton Transactions, 2017, 46, 10758-10773.	1.6	140
2	Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for Preclinical Development. PLoS ONE, 2016, 11, e0153416.	1.1	40
3	A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer. Journal of Controlled Release, 2017, 252, 50-61.	4.8	33
4	Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status. Investigational New Drugs, 2017, 35, 682-690.	1.2	27
5	What Drives Innovation: The Canadian Touch on Liposomal Therapeutics. Pharmaceutics, 2019, 11, 124.	2.0	19
6	Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor. Journal of Controlled Release, 2018, 286, 1-9.	4.8	11
7	Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments. Nanomedicine, 2014, 9, 501-522.	1.7	9
8	Transition Metal Ions Promote the Bioavailability of Hydrophobic Therapeutics: Cu and Zn Interactions with RNA Polymeraseâ€I Inhibitor CX5461. Chemistry - A European Journal, 2018, 24, 6334-6338.	1.7	6
9	DMPC/Chol liposomal copper CX5461 is therapeutically superior to a DSPC/Chol formulation. Journal of Controlled Release, 2022, 345, 75-90.	4.8	4